In this article, we will look at the 7 Best Longevity Stocks to Buy Now.
Longevity stocks are getting more attention as investors look for companies tied to longer lifespans, healthier aging, and rising demand for care. The theme is broader than drugmakers. It includes chronic disease treatment, preventive healthcare, diagnostics, medical technology, fitness, nutrition, telehealth, and active aging.
Pictet Asset Management says “We are living longer,” but adds that the challenge is making sure “those extra years are spent in good health.” The firm expects “preventative health” to become a bigger focus for governments, healthcare companies, and individuals, which supports the case for diagnostics, screening, obesity care, and medtech. UBS describes longevity as an opportunity that helps people “live longer, healthier lives,” and estimates that annual revenues in the global longevity market could reach “USD 8tr” by 2030, with healthcare alone representing a “USD 2.2tr opportunity.” J.P. Morgan Private Bank adds that “Health & Wellness is now experiencing a renaissance,” supported by GLP-1 drugs, an aging global population, telehealth, mental health, and “wearable and fitness technology.” Against this backdrop, longevity stocks deserve a closer look.
With that in mind, let’s take a look at the 7 Best Longevity Stocks to Buy Now.
Our Methodology
We used the Finviz screener to identify longevity stocks that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).
7. Johnson & Johnson (NYSE:JNJ)
On June 8, 2026, Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Firefly Bio, Inc. for $1B in cash. Firefly Bio is advancing its proprietary Firelink degrader antibody conjugate platform, which is focused on KRAS-driven tumors. Johnson & Johnson said the Firelink DAC platform bolsters its oncology pipeline and is designed to deliver a selective protein degrader to tumor cells while avoiding healthy cells. The transaction is expected to close later this year, subject to regulatory approvals and other customary closing conditions.
On June 3, 2026, Johnson & Johnson (NYSE:JNJ) announced new biomarker exploratory analyses from the Phase 2 DAHLIAS study of nipocalimab in adults with moderate-to-severe Sjogren’s disease. The company said patients with elevated autoantibody and immunoglobulin G levels showed greater clinical response rates, with the findings supporting continued study of nipocalimab in the ongoing Phase 3 DAFFODIL study. Also on June 3, Johnson & Johnson said nipocalimab met the primary endpoint in the Phase 2 JASMINE study in adults with moderate-to-severe systemic lupus erythematosus, reducing disease activity at 24 weeks and showing sustained reduction through 52 weeks.
Johnson & Johnson also said the JASMINE study showed greater response versus placebo plus background medication in participants who tested positive for lupus-associated autoantibodies. At Week 52, 53.6% of patients receiving nipocalimab 15 mg/kg achieved an SRI-4 response, compared with 39.7% for placebo plus background medication. The company said nipocalimab had a safety profile consistent with previous studies, and no new safety signals were identified.
Johnson & Johnson (NYSE:JNJ) researches, develops, manufactures, and sells healthcare products worldwide.
6. Amgen Inc. (NASDAQ:AMGN)
On June 7, 2026, Amgen Inc. (NASDAQ:AMGN) announced new data at the American Diabetes Association 86th Scientific Sessions, including Phase 3 VESALIUS-CV subgroup results for Repatha in patients with high-risk diabetes and elevated LDL-C without prior heart attack or stroke. In an analysis of 6,002 patients, Repatha, when added to statins or other LDL-C-lowering therapies, reduced the risk of the composite primary endpoint of coronary heart disease death, myocardial infarction, or ischemic stroke by 29% compared with placebo. Repatha also reduced the risk of a second composite primary endpoint that included ischemia-driven revascularization by 21%.
On June 5, 2026, Goldman Sachs lowered the firm’s price target on Amgen Inc. (NASDAQ:AMGN) to $389 from $425 and maintained a Buy rating on the shares. Goldman Sachs adjusted its model after Amgen disclosed in its Q1 earnings that the IRS audit for 2016 to 2018 had escalated into a formal dispute, with the company receiving a notice of proposed adjustment.
Earlier in June, Amgen announced that the European Commission granted marketing authorization for Imdylltra as a monotherapy for adults with extensive-stage small cell lung cancer who require systemic therapy after disease progression on or after first-line platinum-based chemotherapy.
Amgen Inc. (NASDAQ:AMGN) discovers, develops, manufactures, and delivers human therapeutics worldwide.
While we acknowledge the potential of AMGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AMGN and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the 5 Best Longevity Stocks to Buy Now.
Disclosure: None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center